ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
1-Year Return
26.77%
This Quarter Return
+12.23%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$597M
AUM Growth
+$99.9M
(+20%)
Cap. Flow
+$40.6M
Cap. Flow
% of AUM
6.81%
Top 10 Holdings %
Top 10 Hldgs %
54.95%
Holding
336
New
84
Increased
77
Reduced
72
Closed
71
Top Buys
| 1 |
Immunovant
IMVT
|
$18.7M |
| 2 |
Ascendis Pharma
ASND
|
$16.4M |
| 3 |
Zura Bio
ZURA
|
$15.3M |
| 4 |
Zai Lab
ZLAB
|
$12.3M |
| 5 |
AAM
AA Mission Acquisition Corp.
AAM
|
$10.1M |
Top Sells
| 1 |
Protagonist Therapeutics
PTGX
|
$28M |
| 2 |
Roivant Sciences
ROIV
|
$13M |
| 3 |
Edgewise Therapeutics
EWTX
|
$11.2M |
| 4 |
Merck
MRK
|
$8.47M |
| 5 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$6.96M |
Sector Composition
| 1 | Healthcare | 88.63% |
| 2 | Financials | 3.75% |
| 3 | Communication Services | 0.59% |
| 4 | Utilities | 0.21% |
| 5 | Technology | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Viridian Therapeutics
VRDN
$1.52B
| $209K | 0.03% |
9,206
+1,206
| +15% | +$27.4K |
|
152
Terns Pharmaceuticals
TERN
$617M
| $206K | 0.03% |
24,702
+9,702
| +65% | +$80.9K |
|
153
Fulcrum Therapeutics
FULC
$373M
| $199K | 0.03% |
55,802
-312,567
| -85% | -$1.12M |
|
|
SPRB
154
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
| $192K | 0.03% |
403,716
+48,500
| +14% | +$23K |
|
|
CTNM
155
Contineum Therapeutics
CTNM
$320M
| $172K | 0.03% |
+8,967
| New | +$172K |
|
156
Celldex Therapeutics
CLDX
$1.53B
| $170K | 0.03% |
5,000
+4,697
| +1,550% | +$160K |
|
|
NVEI
157
DELISTED
Nuvei Corporation Subordinate Voting Shares
NVEI
| $167K | 0.03% |
5,000
| – | – |
|
158
NextCure
NXTC
$13.2M
| $164K | 0.03% |
10,001
+2,583
| +35% | +$42.5K |
|
159
KalVista Pharmaceuticals
KALV
$771M
| $164K | 0.03% |
14,143
+2,123
| +18% | +$24.6K |
|
160
Bolt Biotherapeutics
BOLT
$9.69M
| $159K | 0.03% |
12,248
+2,948
| +32% | +$38.2K |
|
161
Abeona Therapeutics
ABEO
$355M
| $154K | 0.03% |
24,322
-88,803
| -78% | -$561K |
|
|
BKHA
162
Black Hawk Acquisition Corp
BKHA
$46.1M
| $154K | 0.03% |
+15,000
| New | +$154K |
|
163
PMV Pharmaceuticals
PMVP
$76.8M
| $151K | 0.02% |
101,008
+51,008
| +102% | +$76K |
|
164
Iovance Biotherapeutics
IOVA
$821M
| $147K | 0.02% |
15,700
-6,700
| -30% | -$62.9K |
|
|
PGRU
165
DELISTED
PropertyGuru Group Limited
PGRU
| $132K | 0.02% |
+20,000
| New | +$132K |
|
166
Biohaven
BHVN
$1.72B
| $132K | 0.02% |
+2,637
| New | +$132K |
|
|
167
Merck
MRK
$211B
| $129K | 0.02% |
1,140
-74,610
| -98% | -$8.47M |
|
168
Perimeter Solutions
PRM
$3.25B
| $121K | 0.02% |
+9,000
| New | +$121K |
|
169
Amplify Energy
AMPY
$160M
| $121K | 0.02% |
18,475
+15,547
| +531% | +$102K |
|
170
TG Therapeutics
TGTX
$5.03B
| $117K | 0.02% |
5,000
-589
| -11% | -$13.8K |
|
171
Quince Therapeutics
QNCX
$84.3M
| $111K | 0.02% |
142,958
+50,000
| +54% | +$38.8K |
|
172
Beyond Air
XAIR
$11.3M
| $109K | 0.02% |
14,107
-47,157
| -77% | -$366K |
|
173
Aclaris Therapeutics
ACRS
$232M
| $104K | 0.02% |
+90,000
| New | +$104K |
|
174
ANI Pharmaceuticals
ANIP
$2.07B
| $101K | 0.02% |
+1,700
| New | +$101K |
|
175
Recursion Pharmaceuticals
RXRX
$2B
| $98.9K | 0.02% |
+15,000
| New | +$98.9K |
|